| Symbol | NCOA2 |
|---|
| Full Name | Nuclear Receptor Coactivator 2 |
|---|
| Chromosome | 8q13.3 |
|---|
| NCBI Gene ID | [10499](https://www.ncbi.nlm.nih.gov/gene/10499) |
|---|
| UniProt ID | [Q15596](https://www.uniprot.org/uniprot/Q15596) |
|---|
| Ensembl ID | [ENSG00000140396](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140396) |
|---|
NCOA2 (Nuclear Receptor Coactivator 2), also known as GRIP1 (Glucocorticoid Receptor-Interacting Protein 1) or TIF2 (Transcriptional Intermediary Factor 2), is a transcriptional coactivator that plays a critical role in nuclear receptor-mediated gene transcription. As a member of the p160/SRC (Steroid Receptor Coactivator) family, NCOA2 serves as a bridge between nuclear receptors and the general transcription machinery, amplifying gene expression programs that are essential for neuronal function, synaptic plasticity, and cellular survival .
NCOA2 is a ~175 kDa protein containing multiple functional domains that mediate protein-protein interactions:
- N-terminal Domain: Contains basic helix-loop-helix (bHLH) and PAS (PER-ARNT-SIM) domains that mediate dimerization and DNA binding .
- C-terminal Activating Domains: Three autonomous activation domains (AD1, AD2, AD3) that recruit coactivators including histone acetyltransferases (CBP/p300), histone methyltransferases, and the Mediator complex .
- LXXLL Motifs: Seven LXXLL motifs that facilitate binding to nuclear receptor AF-2 domains in a ligand-dependent manner .
NCOA2 coactivates numerous nuclear receptors relevant to neurodegeneration:
- Estrogen Receptors (ERα, ERβ): Critical for neuroprotection, mitochondrial function, and cognitive function .
- Glucocorticoid Receptor (GR): Regulates stress response and neuronal viability .
- Thyroid Hormone Receptors (TRα, TRβ): Essential for brain development and myelin maintenance .
- Retinoid X Receptors (RXR): Partners in nuclear receptor heterodimers that regulate gene networks involved in neuronal survival .
- Liver X Receptors (LXR): Regulate cholesterol metabolism and inflammation in the brain .
NCOA2 has several connections to Alzheimer's disease pathogenesis:
- Estrogen Signaling: By coactivating estrogen receptors, NCOA2 participates in estrogen-mediated neuroprotection against amyloid-beta toxicity. Dysregulation of NCOA2 may contribute to the loss of estrogen's neuroprotective effects in post-menopausal women .
- APP Processing: Nuclear receptor signaling involving NCOA2 can modulate amyloid precursor protein (APP) processing and amyloid-beta production through transcriptional regulation of APP-processing enzymes .
- Tau Phosphorylation: Thyroid hormone signaling through NCOA2-coactivated receptors can influence tau kinase and phosphatase activity .
- Mitochondrial Function: NCOA2-mediated activation of ERRα (Estrogen-Related Receptor Alpha) promotes mitochondrial biogenesis and function, which is impaired in AD .
- Dopaminergic Neuron Survival: NCOA2 coactivates receptors that promote survival of dopaminergic neurons. Thyroid hormone (T3) signaling through TRβ, facilitated by NCOA2, has been shown to protect against MPTP-induced parkinsonism .
- Alpha-Synuclein Expression: Nuclear receptor pathways involving NCOA2 may regulate alpha-synuclein expression, though this remains to be fully characterized.
- Neuroinflammation: LXR signaling, which can be enhanced by NCOA2, has anti-inflammatory effects in microglial cells that may be protective in PD .
- Glutamate Excitotoxicity: NCOA2's role in glucocorticoid signaling may influence glutamate excitotoxicity, a key mechanism in ALS pathogenesis .
- Energy Metabolism: Dysregulation of nuclear receptor signaling involved in energy metabolism may contribute to motor neuron degeneration .
- Transcriptional Dysregulation: NCOA2 function is perturbed in HD, contributing to the widespread transcriptional alterations observed in the disease. Restoring NCOA2-mediated transcriptional programs has shown promise in preclinical models .
- BDNF Expression: NCOA2 coactivates receptors that regulate brain-derived neurotrophic factor (BDNF) expression, which is reduced in HD .
- Regional Distribution: NCOA2 is widely expressed throughout the brain, with high levels in the cortex, hippocampus, basal ganglia, and cerebellum .
- Cellular Localization: Expressed in both neurons and glial cells, with particular enrichment in pyramidal neurons and Purkinje cells .
- Subcellular Localization: Primarily nuclear, consistent with its role as a transcriptional coactivator.
NCOA2 expression and activity are regulated at multiple levels:
- Transcriptional Regulation: Induced by nuclear receptor ligands including estrogen, thyroid hormone, and glucocorticoids .
- Post-translational Modifications: Phosphorylation, acetylation, and SUMOylation regulate NCOA2 activity and stability .
- Cellular Signaling: Multiple kinase pathways (MAPK, PKA, Akt) can phosphorylate and activate NCOA2 .
- Xu et al., Crystal structure of NCOA2 ligand-binding domain with nuclear receptors (1999)
- Leo & Chen, The SRC-1 and SRC-2 transcriptional coactivator families (2000)
- McKenna & O'Malley, Combinatorial control of gene expression by nuclear receptors and coactivators (2002)
- Torchia et al., The transcriptional coactivator p/CIP (NCOA3) and related family members (1997)
- Brinton, Estrogen, amyloid, and neurodegeneration (2008)
- Sapolsky, Glucocorticoid toxicity in the hippocampus (1996)
- Bernal, Thyroid hormone receptors in brain development (2000)
- Mangelsdorf & Evans, The RXR heterodimers and orphan receptors (1995)
- Zelcer et al., LXRs regulate lipid metabolism and inflammation in the brain (2006)
- Hiltunen et al., Nuclear receptors regulate APP processing (2009)
- Yang et al., NCOA2 and mitochondrial biogenesis in neurons (2011)
- das Neves et al., Thyroid hormone neuroprotection in PD models (1999)
- Pasinetti, Nuclear receptors and ALS (2006)
- Yohrling et al., Transcriptional dysregulation in HD (2003)
- Zuccato & Cattaneo, BDNF in Huntington's disease (2009)
- NCoA2 expression in mouse brain. Journal of Comparative Neurology (2003)
- Wu et al., Regulation of NCOA2 by post-translational modifications (2006)